Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Inhibitors & Agonists > Others > Other Targets

Lonidamine

  Cat. No.:  DCAPI1199   Featured
Chemical Structure
50264-69-2
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86 21 58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis.
Chemicals PropertiesBiological activity Related products COA MSDS Datasheet
Cas No.: 50264-69-2
Chemical Name: Lonidamine
Synonyms: 1-(2,4-Dichlorobenzyl)-1H-indazole-3-carboxylic acid;1-(2,4-Dichlorobenzyl)indazole-3-carboxylic acid;Lonidamine;1-[(2,4-Dichlorophenyl)methyl]-1H-indazole-3-carboxylic acid;1-[(2,4-dichlorophenyl)methyl]indazole-3-carboxylic acid;1-(2,4-Dichlorobenzyl)-1H-indazole-3-carboxylic acid Diclondazolic acid;AF1890;DICA;Diclondazolic acid;Doridamina;Lonidamin;Lonidamina;Lonidaminum;Lonidaminum [INN-Latin];AF 1890;Lonidamina [INN-Spanish];1-(2,4-Dichlorbenzyl)-indazole-3-carboxylic acid;MLS000028822;C15H10Cl2N2O;AF-1890;NCGC00025244-02;Lonidamine (INN);HMS2234H24;Lonidamine [INN:BAN];D07257;LONIDAMINE [WHO-DD];HMS3262O17;SR-01000075961;NCGC00261403-01;AB00597141_08;SR-01000075961-1;Lopac0_000718;LONIDAMINE [INN];Q3836670;GTPL12601;NS00032024;s2610;C15H10Cl2N2O2;SW219810-1;LONIDAMINE [MI];NCGC00015609-01;NCGC00015609-07;50264-69-2;HMS3874D03;HMS3676P05;NSC 758419;NCGC00015609-08;NCGC00015609-02;Tox21_110181;1H-Indazole-3-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]-;NSC741419;UNII-U78804BIDR;SCHEMBL7134;1H-Indazole-3-carboxylic acid, 1-(2,4-dichlorobenzyl)-;WDRYRZXSPDWGEB-UHFFFAOYSA-N;HMS3651F09;Q-201318;HY-B0486;SDCCGSBI-0050696.P003;NSC-758419;Lonidamine, mitochondrial hexokinase inhibitor;NSC-741419;BRD-K78513633-001-03-3;SR-01000075961-3;SMR000058467;EN300-345010;MFCD00866285;CCRIS 3516;LP00718;NSC 741419;SR-01000075961-6;Tox21_500718;KN-228;CHEMBL1257030;NCGC00015609-03;BRD-K78513633-001-06-6;HMS3369I01;EINECS 256-510-0;AF-1890;Diclondazolic Acid;DICA;HMS3412P05;cid_39562;L0283;DTXCID90782;CCG-204803;Z1137008901;BRN 0894483;HMS3268K09;DTXSID5020782;Doridamina (TN);BDBM59775;1-[(2,4-Dichlorophenyl)Methyl]-1H-indazole-3-carboxylicacid;BCP06555;HB0993;LONIDAMINE [MART.];AKOS012842739;FT-0650359;AM20060642;A929099;NSC758419;AS-11653;NCGC00025244-01;AB00597141_10;Tocris-1646;DB06266;CAS-50264-69-2;NCGC00015609-09;Tox21_110181_1;NCGC00015609-16;1H-Indazole-3-carboxylic acid, 1-((2,4-dichlorophenyl)methyl)-;NCGC00025244-03;1-[(2,4-dichlorophenyl)methyl]-3-indazolecarboxylic acid;EU-0100718;SBI-0050696.P002;NCGC00015609-05;NCGC00015609-04;NCGC00015609-06;Tox21_202306;TH-070;AC-5626;L 4900;CHEBI:50138;Dichlondazolic acid;U78804BIDR;NCGC00259855-01;Pharmakon1600-01503225;Lopac-L-4900;L01XX07;Lonidaminum (INN-Latin);BRD-K78513633-001-13-2;lonidamine;1H-Indazole-3-carboxylic acid, 1-((2,4-dichlorophenyl)methyl)-(9CI);BRD-K78513633-001-14-0;LONIDAMINE (MART.);1-[(2,4-dichlorophenyl)methyl]-1H-indazole-3-carboxylic acid;1-(2,4-dichlorobenzyl)indazole-3-carboxylic acid;Lonidamine?;1-((2,4-dichlorophenyl)methyl)indazole-3-carboxylic acid;Lonidamina (INN-Spanish);1-(2,4-dichlorophenyl)-1h-indazol-3-carboxylic acid;BRD-K78513633-001-15-7;Diclondazolic Acid
SMILES: ClC1C([H])=C(C([H])=C([H])C=1C([H])([H])N1C2=C([H])C([H])=C([H])C([H])=C2C(C(=O)O[H])=N1)Cl
Formula: C15H10Cl2N2O2
M.Wt: 321.1581
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Lonidamine is an orally administered small molecule hexokinase inactivator.Target: OthersLonidamine is a derivative of indazole-3-carboxylic acid, which for a long time, has been known to inhibit aerobic glycolysis in cancer cells. It seems to enhance aerobic glycolysis in normal cells, but suppress glycolysis in cancer cells. This is most likely through the inhibition of the mitochondrially bound hexokinase. Later studies in Ehrlich ascites tumor cells showed that lonidamine inhibits both respiration and glycolysis leading to a decrease in cellular ATP. Clinical trials of lonidamine in combination with other anticancer agents for a variety of cancers has begun. Lonidamine has been used in the treatment of brain tumours in combination with radiotherapy and temozolomide. Results showed that a combination of temozolomide and lonidamine at clinically achievable, low plasma concentrations, could inhibit tumour growth, and lonidamine could reduce the dose of temozolomide required for radiosensitization of brain tumours. From Wikipedia.
Cat. No. Product name Field of application
DC82301 IC-8 IC8 is an ionizable cationic lipid. It has been used in combination with other lipids for the formation of lipid nanoparticles (LNPs). Immunization with severe acute respiratory coronavirus 2 (SARS-CoV-2) spike glycoprotein mRNA in IC8- and manganese-containing LNPs induces IgG responses to SARS-CoV-2 Delta and Omicron variants in mice.1 Administration of mRNA encoding B7-H3 X CD3 bispecific T cell engaging (BiTE) antibodies in IC8-containing LNPs reduces tumor growth in MV4-11 and A375 mouse xenograft models.
DC75721 CL2A-SN38 (Govitecan) CL2A-SN38 is a SN38 derivative with a peptide-linker which can easily react with antibody to form an antibody-drug conjugate (ADC). CL2A-SN-38 is composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a noncleavable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. .
DC46471 RP101988 RP101988, the major active metabolite of Ozanimod, is a selective, potent S1PR1 (sphingosine-1-phosphate receptor 1) agonist, with EC50s of 0.19 nM and 32.8 nM for S1PR1 and S1PR5, respectivlely.
DC37901 PD-173212 PD-173212 is a small molecule N-type calcium channel blocker.
DC37333 N,N-Diethyl-p-toluamide N,N-Diethyl-p-toluamide is a mosquito repellent.
DC37321 AI3-15902 AI3-15902 is a biochemical.
DC37283 Methyl phenylcarbamate Methyl phenylcarbamate is a biochemical.
DC37252 Ampyrone Ampyrone is a metabolite of AMINOPYRINE with analgesic and anti-inflammatory properties. It is used as a reagent for biochemical reactions producing peroxides or phenols. Ampyrone stimulates LIVER MICROSOMES and is also used to measure extracellular water.
DC37245 Piperonyl butoxide Piperonyl butoxide (PBO) is an organic compound used as a component of pesticide formulations. It is a waxy white solid. It is a synergist. That is, despite having no pesticidal activity of its own, it enhances the potency of certain pesticides such as carbamates, pyrethrins, pyrethroids, and rotenone.[1] It is a semisynthetic derivative of safrole.
DC34632 MDL800 MDL-800 is a first-in-class cellularly active SIRT6 allosteric activator.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia